StemPoint Capital LP Acquires 9.9% Stake in Sensei Biotherapeutics, Inc. (SNSE)

On May 15, 2026, StemPoint Capital LP, alongside StemPoint Capital Management GP LLC and Michelle Ross, filed a Schedule 13G disclosing a significant new stake in Sensei Biotherapeutics, Inc. (SNSE). The reporting persons collectively reported beneficial ownership of 132,873 shares of Common Stock, representing a 9.9% ownership stake in the company based on shares outstanding as of March 23, 2026. This filing marks an increase from a previously reported 0.0% position, establishing StemPoint Capital as a major shareholder. The shares are held for investment purposes in the ordinary course of business, with shared dispositive power over all 132,873 shares and shared voting power over 116,587 shares. The filing was triggered by an event on March 31, 2026. StemPoint Capital LP is a Delaware limited partnership, and Michelle Ross is a U.S. citizen. The joint filing agreement confirms that all three entities are responsible for the accuracy of the reported information.